滤泡性淋巴瘤患者接受 B 细胞清除疗法后 B 细胞恢复，SARS-CoV-2 持续感染得以缓解

IF 0.8 Q4 RESPIRATORY SYSTEM

Respiratory Medicine Case Reports Pub Date : 2024-01-01 DOI:10.1016/j.rmcr.2024.102131

Yuriko Sueda , Hirokazu Tokuyasu , Momoka Atsuta , Hiromitsu Sakai , Katsunori Arai , Chika Esumi , Misato Mochizuki , Tomoki Itohara , Naoki Fujisawa , Akira Yamasaki

{"title":"滤泡性淋巴瘤患者接受 B 细胞清除疗法后 B 细胞恢复，SARS-CoV-2 持续感染得以缓解","authors":"Yuriko Sueda , Hirokazu Tokuyasu , Momoka Atsuta , Hiromitsu Sakai , Katsunori Arai , Chika Esumi , Misato Mochizuki , Tomoki Itohara , Naoki Fujisawa , Akira Yamasaki","doi":"10.1016/j.rmcr.2024.102131","DOIUrl":null,"url":null,"abstract":"<div><div>A 68-year-old woman with follicular lymphoma was treated with chemotherapy, including the anti-CD20 monoclonal antibody obinutuzumab, and achieved remission. A month after the administration of obinutuzumab, the patient contracted coronavirus disease 2019 (COVID-19), and various antiviral drugs were administered. However, the infection had not been eliminated. One year and three months after chemotherapy, peripheral B cell recovery was achieved, and the infection had resolved. This report provides insight into the course of COVID-19 in patients with impaired humoral immunity.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"52 ","pages":"Article 102131"},"PeriodicalIF":0.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Persistent SARS-CoV-2 infection resolved after B-cell recovery in a patient with follicular lymphoma treated with B-cell depletion therapy\",\"authors\":\"Yuriko Sueda , Hirokazu Tokuyasu , Momoka Atsuta , Hiromitsu Sakai , Katsunori Arai , Chika Esumi , Misato Mochizuki , Tomoki Itohara , Naoki Fujisawa , Akira Yamasaki\",\"doi\":\"10.1016/j.rmcr.2024.102131\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>A 68-year-old woman with follicular lymphoma was treated with chemotherapy, including the anti-CD20 monoclonal antibody obinutuzumab, and achieved remission. A month after the administration of obinutuzumab, the patient contracted coronavirus disease 2019 (COVID-19), and various antiviral drugs were administered. However, the infection had not been eliminated. One year and three months after chemotherapy, peripheral B cell recovery was achieved, and the infection had resolved. This report provides insight into the course of COVID-19 in patients with impaired humoral immunity.</div></div>\",\"PeriodicalId\":51565,\"journal\":{\"name\":\"Respiratory Medicine Case Reports\",\"volume\":\"52 \",\"pages\":\"Article 102131\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory Medicine Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213007124001540\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213007124001540","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

一名患有滤泡性淋巴瘤的 68 岁妇女接受了包括抗 CD20 单克隆抗体奥比乌珠单抗在内的化疗，并取得了缓解。服用奥比奴珠单抗一个月后，患者感染了冠状病毒病 2019（COVID-19），并服用了各种抗病毒药物。然而，感染并未消除。化疗一年零三个月后，外周 B 细胞恢复，感染也已消除。本报告为体液免疫受损患者的COVID-19病程提供了深入见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Persistent SARS-CoV-2 infection resolved after B-cell recovery in a patient with follicular lymphoma treated with B-cell depletion therapy

A 68-year-old woman with follicular lymphoma was treated with chemotherapy, including the anti-CD20 monoclonal antibody obinutuzumab, and achieved remission. A month after the administration of obinutuzumab, the patient contracted coronavirus disease 2019 (COVID-19), and various antiviral drugs were administered. However, the infection had not been eliminated. One year and three months after chemotherapy, peripheral B cell recovery was achieved, and the infection had resolved. This report provides insight into the course of COVID-19 in patients with impaired humoral immunity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊